JP2008525397A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008525397A5 JP2008525397A5 JP2007547621A JP2007547621A JP2008525397A5 JP 2008525397 A5 JP2008525397 A5 JP 2008525397A5 JP 2007547621 A JP2007547621 A JP 2007547621A JP 2007547621 A JP2007547621 A JP 2007547621A JP 2008525397 A5 JP2008525397 A5 JP 2008525397A5
- Authority
- JP
- Japan
- Prior art keywords
- piperazine
- dichlorophenyl
- carboxamide
- induced
- rhinitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 206010039083 rhinitis Diseases 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- -1 sodium cyanamide hydride Chemical compound 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OSBIEFWIIINTNJ-UHFFFAOYSA-N 1,2-dichloro-4-isothiocyanatobenzene Chemical compound ClC1=CC=C(N=C=S)C=C1Cl OSBIEFWIIINTNJ-UHFFFAOYSA-N 0.000 description 1
- SVOPXXXMGIBMEU-GOSISDBHSA-N 1-(3,4-dichlorophenyl)-4-[[(3R)-1-(2-thiophen-2-ylethyl)piperidin-3-yl]methyl]piperazine Chemical compound ClC=1C=C(C=CC1Cl)N1CCN(CC1)C[C@H]1CN(CCC1)CCC=1SC=CC1 SVOPXXXMGIBMEU-GOSISDBHSA-N 0.000 description 1
- JWOHBPPVVDQMKB-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC(C(O)=O)CC1 JWOHBPPVVDQMKB-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- 208000035939 Alveolitis allergic Diseases 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010065563 Eosinophilic bronchitis Diseases 0.000 description 1
- 208000027445 Farmer Lung Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- FDNWPLIXGPCYGG-UHFFFAOYSA-N N1(CCNCC1)C(=O)NC(=O)C1CNCCO1 Chemical compound N1(CCNCC1)C(=O)NC(=O)C1CNCCO1 FDNWPLIXGPCYGG-UHFFFAOYSA-N 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 206010039094 Rhinitis perennial Diseases 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 201000009151 chronic rhinitis Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 208000022195 farmer lung disease Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- GEYPMIWNYDNWIJ-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-4-[4-(2-phenylethyl)morpholine-2-carbonyl]piperazine-1-carboxamide Chemical compound C1=C(Cl)C(Cl)=CC=C1NC(=O)N1CCN(C(=O)C2OCCN(CCC=3C=CC=CC=3)C2)CC1 GEYPMIWNYDNWIJ-UHFFFAOYSA-N 0.000 description 1
- PSNFRABGKGKWCA-KRWDZBQOSA-N n-(3,4-dichlorophenyl)-4-[[(3s)-1-(2-thiophen-2-ylacetyl)piperidin-3-yl]methyl]piperazine-1-carboxamide Chemical compound C1=C(Cl)C(Cl)=CC=C1NC(=O)N1CCN(C[C@H]2CN(CCC2)C(=O)CC=2SC=CC=2)CC1 PSNFRABGKGKWCA-KRWDZBQOSA-N 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000022719 perennial allergic rhinitis Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- DTUQWGWMVIHBKE-UHFFFAOYSA-N phenylacetaldehyde Chemical compound O=CCC1=CC=CC=C1 DTUQWGWMVIHBKE-UHFFFAOYSA-N 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 208000017022 seasonal allergic rhinitis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000003156 vasculitic effect Effects 0.000 description 1
- 208000001319 vasomotor rhinitis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0428327A GB0428327D0 (en) | 2004-12-24 | 2004-12-24 | Method |
| GB0428327.1 | 2004-12-24 | ||
| GB0520325A GB0520325D0 (en) | 2005-10-06 | 2005-10-06 | Method |
| GB0520325.2 | 2005-10-06 | ||
| PCT/GB2005/004895 WO2006067401A1 (en) | 2004-12-24 | 2005-12-19 | Heterocyclic compounds as ccr2b antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012176224A Division JP2012214507A (ja) | 2004-12-24 | 2012-08-08 | Ｃｃｒ２ｂアンタゴニストとしてのヘテロ環式化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008525397A JP2008525397A (ja) | 2008-07-17 |
| JP2008525397A5 true JP2008525397A5 (https=) | 2009-02-19 |
| JP5118975B2 JP5118975B2 (ja) | 2013-01-16 |
Family
ID=36084353
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007547621A Expired - Fee Related JP5118975B2 (ja) | 2004-12-24 | 2005-12-19 | Ｃｃｒ２ｂアンタゴニストとしてのヘテロ環式化合物 |
| JP2012176224A Pending JP2012214507A (ja) | 2004-12-24 | 2012-08-08 | Ｃｃｒ２ｂアンタゴニストとしてのヘテロ環式化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012176224A Pending JP2012214507A (ja) | 2004-12-24 | 2012-08-08 | Ｃｃｒ２ｂアンタゴニストとしてのヘテロ環式化合物 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US7906645B2 (https=) |
| EP (1) | EP1831164A1 (https=) |
| JP (2) | JP5118975B2 (https=) |
| KR (1) | KR20070091677A (https=) |
| AR (1) | AR053109A1 (https=) |
| AU (2) | AU2005317928B2 (https=) |
| BR (1) | BRPI0519288A2 (https=) |
| CA (1) | CA2589748C (https=) |
| IL (1) | IL183665A (https=) |
| MX (1) | MX2007007428A (https=) |
| MY (1) | MY147400A (https=) |
| NO (1) | NO20073729L (https=) |
| NZ (1) | NZ555770A (https=) |
| RU (1) | RU2423349C2 (https=) |
| TW (1) | TW200633979A (https=) |
| UY (1) | UY29312A1 (https=) |
| WO (1) | WO2006067401A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2872813B1 (fr) | 2004-07-09 | 2007-01-19 | Sanofi Synthelabo | Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique |
| JPWO2006028161A1 (ja) * | 2004-09-09 | 2008-05-08 | 財団法人乙卯研究所 | セロトニン５−ｈｔ３受容体作動薬 |
| FR2876692B1 (fr) | 2004-10-19 | 2007-02-23 | Sanofi Aventis Sa | Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique |
| AU2005317928B2 (en) * | 2004-12-24 | 2010-06-10 | Astrazeneca Ab | Heterocyclic compounds as CCR2b antagonists |
| KR101336106B1 (ko) | 2005-09-16 | 2013-12-05 | 얀센 파마슈티카 엔.브이. | 히스타민 ｈ3 수용체의 조절제로서 사이클로프로필 아민 |
| GB0525957D0 (en) * | 2005-12-21 | 2006-02-01 | Astrazeneca Ab | Methods |
| WO2007079003A2 (en) * | 2005-12-29 | 2007-07-12 | Bayer Schering Pharma Aktiengesellschaft | Amide inhibitors of leukotriene a4 hydrolase |
| FR2895989B1 (fr) * | 2006-01-06 | 2010-04-30 | Sanofi Aventis | Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique |
| WO2008013622A2 (en) | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
| US9090604B2 (en) | 2006-07-27 | 2015-07-28 | E I Du Pont De Nemours And Company | Fungicidal azocyclic amides |
| US20110172230A1 (en) * | 2006-08-23 | 2011-07-14 | Takahiro Ishii | Urea compound or salt thereof |
| DK2076508T3 (da) | 2006-10-18 | 2011-02-21 | Pfizer Prod Inc | Biaryl-ether-urinstof-forbindelser |
| CA2669917A1 (en) | 2006-11-17 | 2008-05-22 | Dawn M. George | Aminopyrrolidines as chemokine receptor antagonists |
| HRP20170621T1 (hr) | 2006-12-14 | 2017-07-28 | Janssen Pharmaceutica N.V. | Postupak za pripremanje derivata piperazinil i diazepanil benzamida |
| CA2687931C (en) * | 2007-05-31 | 2016-05-24 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists and uses thereof |
| CN102089289A (zh) * | 2008-07-16 | 2011-06-08 | 弗·哈夫曼-拉罗切有限公司 | 用于治疗心血管疾病的新的杂环基化合物 |
| US20100152197A1 (en) * | 2008-12-15 | 2010-06-17 | Astrazeneca Ab | (4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives |
| WO2011114148A1 (en) | 2010-03-17 | 2011-09-22 | Astrazeneca Ab | 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists |
| AU2012256237B2 (en) | 2011-05-13 | 2017-01-05 | Array Biopharma Inc. | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TrkA kinase inhibitors |
| KR102598203B1 (ko) | 2019-11-25 | 2023-11-03 | 암젠 인크 | 델타-5 불포화효소 억제제로서의 헤테로시클릭 화합물 및 사용 방법 |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
| WO2024167423A1 (en) | 2023-02-07 | 2024-08-15 | Captor Therapeutics S.A. | Gspt1 degrader compounds |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3133061A (en) * | 1962-11-13 | 1964-05-12 | Sterling Drug Inc | Piperidine carboxamides and derivatives thereof |
| US3541085A (en) * | 1969-05-09 | 1970-11-17 | American Cyanamid Co | Method of preparing thiotricyclic compounds |
| JPS5331669A (en) | 1976-09-06 | 1978-03-25 | Kissei Pharmaceut Co Ltd | Novel n-acylpiperidinecaroxyanilide derivatives and their preparation |
| JPH0680054B2 (ja) * | 1985-06-19 | 1994-10-12 | 吉富製薬株式会社 | ピペリジン誘導体 |
| DE3636278A1 (de) | 1986-10-24 | 1988-05-05 | Hoechst Ag | Herbizide mittel auf der basis von cyclischen (alpha)-iminocarbon-saeureaniliden sowie neue (alpha)-iminocarbonsaeureanilide und verfahren zu ihrer herstellung |
| IL95994A0 (en) * | 1989-11-15 | 1991-07-18 | American Home Prod | Carbamate esters and pharmaceutical compositions containing them |
| JP2864489B2 (ja) * | 1991-02-27 | 1999-03-03 | 吉富製薬株式会社 | 喘息治療剤 |
| AU2000092A (en) * | 1991-06-21 | 1993-01-25 | Boehringer Mannheim Italia S.P.A. | 2-amino-4-aryl-thiazoles with antiasthmatic and anti-inflammatory activities on the respiratory tract |
| NZ240863A (en) | 1991-09-11 | 1995-04-27 | Mcneilab Inc | Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof |
| CA2077252C (en) | 1992-08-31 | 2001-04-10 | Khashayar Karimian | Methods of making ureas and guanidines, and intermediates therefor |
| DE4234295A1 (de) | 1992-10-12 | 1994-04-14 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| HUP9802363A3 (en) | 1995-10-25 | 1999-04-28 | Du Pont | Herbicidal sulfonamide derivatives, herbicide compositions containing these compounds as active ingredients and use thereof |
| AUPO735997A0 (en) * | 1997-06-17 | 1997-07-10 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives |
| EP1009405A4 (en) * | 1997-08-28 | 2001-05-09 | Merck & Co Inc | PAYRROLIDINE AND PIPERIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY |
| DE19743435A1 (de) | 1997-10-01 | 1999-04-08 | Merck Patent Gmbh | Benzamidinderivate |
| AU2056800A (en) * | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | Heterocyclic piperidines as modulators of chemokine receptor activity |
| AR025884A1 (es) | 1999-10-01 | 2002-12-18 | Takeda Pharmaceutical | Compuestos de amina ciclica, su produccion y su uso |
| US6506751B1 (en) * | 1999-11-12 | 2003-01-14 | Millennium Pharmaceuticals, Inc. | Thiazolidinone compounds useful as chemokine inhibitors |
| AR033517A1 (es) * | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| US6964974B2 (en) * | 2000-09-08 | 2005-11-15 | Hoffmann-La Roche Inc. | 2,3-oxidosqualene-lanosterol cyclase inhibitors |
| US20040082589A1 (en) * | 2000-11-13 | 2004-04-29 | Carlo Farina | Quinoline derivatives as nk-3 and nk-2 antagonists |
| GB0031088D0 (en) | 2000-12-20 | 2001-01-31 | Smithkline Beecham Plc | Medicaments |
| WO2002079151A1 (en) | 2001-03-29 | 2002-10-10 | Smithkline Beecham P.L.C. | 3-substituted indoels or fused pyrroles as antagonists of the chemokine mcp-1 (ccr2b) receptor |
| NZ534582A (en) | 2002-02-27 | 2006-03-31 | Pfizer Prod Inc | ACC inhibitors |
| DK1522314T3 (da) * | 2002-06-26 | 2014-05-26 | Ono Pharmaceutical Co | Midler for sygdomme forårsaget af vaskulær sammentrækning eller udvidelse |
| WO2004041777A2 (en) * | 2002-10-30 | 2004-05-21 | Merck & Co., Inc. | Heteroarylpiperidine modulators of chemokine receptor activity |
| MXPA05005660A (es) | 2002-11-27 | 2005-10-18 | Incyte Corp | Derivados de 3-aminopirrolidina como moduladores de receptores de quimocina. |
| US20040147502A1 (en) * | 2002-12-17 | 2004-07-29 | Bisacchi Gregory S. | Beta lactam compounds and their use as inhibitors of tryptase |
| GB0308801D0 (en) | 2003-04-16 | 2003-05-21 | Celltech R&D Ltd | Chemical compounds |
| EP1719762B1 (en) * | 2004-02-27 | 2012-06-27 | Eisai R&D Management Co., Ltd. | Novel pyridine derivative and pyrimidine derivative (1) |
| FR2872813B1 (fr) * | 2004-07-09 | 2007-01-19 | Sanofi Synthelabo | Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique |
| ES2315695T3 (es) * | 2004-08-09 | 2009-04-01 | Medigene Ltd. | Oxopirazolocinolinas inmunomoduladoras como inhibidores de moleculas cd80. |
| GB0419072D0 (en) * | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
| AU2005317928B2 (en) | 2004-12-24 | 2010-06-10 | Astrazeneca Ab | Heterocyclic compounds as CCR2b antagonists |
| GB0525957D0 (en) | 2005-12-21 | 2006-02-01 | Astrazeneca Ab | Methods |
| US20100152197A1 (en) * | 2008-12-15 | 2010-06-17 | Astrazeneca Ab | (4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives |
-
2005
- 2005-12-19 AU AU2005317928A patent/AU2005317928B2/en not_active Ceased
- 2005-12-19 JP JP2007547621A patent/JP5118975B2/ja not_active Expired - Fee Related
- 2005-12-19 EP EP05820651A patent/EP1831164A1/en not_active Withdrawn
- 2005-12-19 MX MX2007007428A patent/MX2007007428A/es active IP Right Grant
- 2005-12-19 KR KR1020077016875A patent/KR20070091677A/ko not_active Abandoned
- 2005-12-19 NZ NZ555770A patent/NZ555770A/en not_active IP Right Cessation
- 2005-12-19 WO PCT/GB2005/004895 patent/WO2006067401A1/en not_active Ceased
- 2005-12-19 BR BRPI0519288-9A patent/BRPI0519288A2/pt not_active IP Right Cessation
- 2005-12-19 US US11/793,606 patent/US7906645B2/en not_active Expired - Fee Related
- 2005-12-19 CA CA2589748A patent/CA2589748C/en not_active Expired - Fee Related
- 2005-12-19 RU RU2007130144/04A patent/RU2423349C2/ru not_active IP Right Cessation
- 2005-12-22 MY MYPI20056171A patent/MY147400A/en unknown
- 2005-12-23 UY UY29312A patent/UY29312A1/es not_active Application Discontinuation
- 2005-12-23 TW TW094146424A patent/TW200633979A/zh unknown
- 2005-12-26 AR ARP050105527A patent/AR053109A1/es not_active Application Discontinuation
-
2007
- 2007-06-04 IL IL183665A patent/IL183665A/en not_active IP Right Cessation
- 2007-07-18 NO NO20073729A patent/NO20073729L/no not_active Application Discontinuation
-
2010
- 2010-08-13 AU AU2010212346A patent/AU2010212346B2/en not_active Ceased
-
2011
- 2011-02-01 US US13/018,783 patent/US20110136820A1/en not_active Abandoned
-
2012
- 2012-06-07 US US13/490,765 patent/US20120264762A1/en not_active Abandoned
- 2012-08-08 JP JP2012176224A patent/JP2012214507A/ja active Pending
-
2013
- 2013-09-13 US US14/025,939 patent/US8710224B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008525397A5 (https=) | ||
| US8394962B2 (en) | Method for the preparation of dabigatran and its intermediates | |
| ES2287782T3 (es) | Derivados de n-(heteroaril(piperidin-2-il)metil)benzamida, su preparacion y su aplicacion en terapeutica. | |
| AU2001281972B2 (en) | Piperidine coumpounds for use as CCR-3 inhibitors | |
| DE69634806T2 (de) | Substituierte heterocyclische Verbindungen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen | |
| EP0707006B1 (de) | Aroyl-piperidin-Derivate | |
| MX2007001550A (es) | Compuestos de hidroxiamida que tienen actividad como inhibidores de histona desacetilasa (hdac). | |
| ES2335519T3 (es) | Derivados del pirrol que tienen actividad antagonista del receptor crth2. | |
| HU211968A9 (en) | Heterocyclic amines useful in the therapy of asthma and inflammation of the respiratory tract | |
| CA2724998A1 (en) | Nicotinamide derivatives | |
| AU2005272389B2 (en) | Novel cyclic aminobenzoic acid derivative | |
| WO2009129370A1 (en) | Cathepsin c inhibitors | |
| JP2009167215A (ja) | 新規ジアリールアルケン誘導体及び新規ジアリールアルカン誘導体 | |
| DK2059503T3 (en) | Aminopyrazole derivatives, processes for their preparation, and compositions containing these derivatives for the prevention or treatment of ischemic diseases | |
| BE1009571A3 (fr) | Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant. | |
| KR20100065377A (ko) | ２- 및 ３-위치에서 치환된 ５,６-디아릴 피리딘, 그의 제법, 및 그의 치료학적 용도 | |
| JP2008525359A (ja) | Ｍ３アンタゴニストとしての第４級アンモニウム塩類 | |
| WO1994007856A1 (en) | 1,4-disubstituted piperazines useful in the therapy of the asthma and of the inflammation of the respiratory tract | |
| CA2530310C (en) | Substituted diketopiperazines and their use as oxytocin antagonists | |
| CA2912735A1 (en) | Novel tetrazolone derivatives | |
| WO2005035528A2 (en) | Triazole derivatives as antibacterial agents | |
| CN101208302A (zh) | 作为天冬氨酸蛋白酶ii抑制剂的新型4-胺基哌啶衍生物 | |
| WO2002030892A1 (de) | Butenolid- und pentenolidderivate als kinase inhibitoren | |
| KR102325422B1 (ko) | 엔테로펩티다아제 억제 활성을 나타내는 신규 화합물 | |
| HK1041881A1 (en) | Substituted heterocyclic compounds, their process of preparation and pharmaceutical compositions containing them |